<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03593005</url>
  </required_header>
  <id_info>
    <org_study_id>2018-00455_B2</org_study_id>
    <nct_id>NCT03593005</nct_id>
  </id_info>
  <brief_title>Acute Exposure to High Altitude on Symptoms</brief_title>
  <official_title>Acute Exposure to Hypoxia in Precapillary Pulmonary Hypertension: Physiological and Clinical Effects at Rest and During Exercise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized crossover Trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the
      acute response to High Altitude (2500m above sea level) in altitude related symptoms
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Low altitude baseline measurements will be performed in Zurich (460m asl) including
      Echocardiography, Right heart catheterization, 6MWT, pulmonary function test, clinical
      assessment and blood gas Analysis.

      Randomly assigned to the order of testing, the participants will be tested at Low Altitude
      (Zurich, 470m) and High Altitude (2500m).

      Regularly during the exposure of approximately 5 hours, the participants will be asked to
      complete altitude related symptom questionnaires
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Actual">January 1, 2019</completion_date>
  <primary_completion_date type="Actual">January 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Including a baseline assessment and assessments at Low altitude and High altitude</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Altitude related symptoms at High Altitude</measure>
    <time_frame>5 hours</time_frame>
    <description>Completion of altitude related questionnaires during the exposure to the Elevation of 2500m above sea level</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Order A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants will be tested in the following order: Zurich (Low altitude: 470m above sea level) and consecutively High Altitude (Säntis; 2500m above sea Level)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Order B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assessment at Low Altitude (470m above sea level)</intervention_name>
    <description>Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure</description>
    <arm_group_label>Order A</arm_group_label>
    <arm_group_label>Order B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exposure to High Altitude (2500m above sea level)</intervention_name>
    <description>Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours</description>
    <arm_group_label>Order A</arm_group_label>
    <arm_group_label>Order B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  PH diagnosed according to internation Guidelines: mPAP ≥ 25 mmHg along with a PAWP ≤15
             mmHg during right heart catheterization at the time of Initial diagnosis

          -  PH class 1 (PAH) or 4 (CTEPH)

          -  Stable condition, on the same medication for &gt; 4 weeks

          -  Patient live permanently at an altitude &lt; 1000m asl.

        Exclusion Criteria:

          -  Resting PaO2 ≤7.3 kPA corresponding to the requirement of long-term oxygen therapy &gt;
             16hour daily (nocturnal oxygen therapy alone is allowed)

          -  Severe daytime hypercapnia (pCO2 &gt; 6.5 kPa)

          -  Susceptibility to high altitude related diseases (AMS, HAPE, etc.) based on previous
             experienced discomfort at altitudes.

          -  Exposure to an altitude &gt;1500m for ≥3 nights during the last 4 weeks before the study
             participation

          -  Residence &gt; 1000m above sea level

          -  Inability to follow the procedures of the study, e.g. due to language problems,
             psychological disorders, neurological or orthopedic problems with Walking disability

          -  Women who are pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvia Ulrich, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Respiratory Clinic, University Hospital of Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 9, 2018</study_first_submitted>
  <study_first_submitted_qc>July 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2018</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High Altitude</keyword>
  <keyword>Altitude related symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

